Crosslinking insurance reimbursement finally available in Switzerland
Exactly 20 years after the clinical introduction of cross-linking and after more than 2,000 scientific publications on the subject, corneal cross-linking (CXL) for the treatment of progressive keratoconus has now been included in the Swiss healthcare reimbursement system (the “Krankenkasse”).
The amount that will be reimbursed by insurers has not yet been determined.
Speaking on behalf of the ELZA Institute, its Medical Director, Prof. Farhad Hafezi had the following to say:
“We are very happy about this decision. In 2021, we had several patients with keratoconus who needed CXL treatment, who we treated for free, for humanitarian reasons. Most were children and adolescents, where their families could not afford the treatment.”
Today, the “Tages-Anzeiger” and “Beobachter” newspapers reported the news about crosslinking insurance reimbursement in Switzerland, featuring Prof. Hafezi in their coverage. Our previous article in “Beobachter” from 2018 certainly helped to get the ball rolling for the change of the law.
We would like to express our many and sincere thanks to both “Beobachter” and “Tages-Anzeiger” for their engagement.
